1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Regulation

Dual Rx/OTC Status In US ‘Additional Condition’ Switch Proposal: Necessary Or Questionable?

FDA Shift In Requirements For OTC Switch Follow-On Approvals Also Discussed By Experts

 
• By Malcolm Spicer

OTC drug development and marketing consultants discuss FDA allowing simultaneous Rx and OTC sales of same drug formulation with the same indication and about opportunities for follow-on generic equivalents of switches approved as additional condition for nonprescription use OTCs.

• Source: Shutterstock

A proposed US rule to facilitate OTC switches for chronic conditions would bend two basic rules of drug regulation, one keeping approvals of Rx and nonprescription drugs separate and the other setting approval requirements for follow-on generic equivalents of switched products.

Both pieces of the Food and Drug Administration’s “Nonprescription Drug Product with an Additional Condition for Nonprescription Use” proposed...

Welcome to HBW Insight

Create an account to read this article

Already a subscriber?

More from Regulation

US FDA Facility Inspections, Website Reviews Paused With FY 2026 Budget On Hold

 
• By Malcolm Spicer

Continuing work includes “for cause and certain surveillance inspections of regulated facilities” and “criminal enforcement work and certain civil investigations” as White House mulls layoffs rather than furloughs during federal government shutdown.

OMUFA Reauthorization: US FDA Would Identify Rx-OTC Switch Candidates, Work With Sponsors

 
• By Kate Rawson

Senate “SMART OTC” Act would require the FDA to identify product categories that could be eligible for an Rx-to-OTC switch and create a framework to work with sponsors.

Women’s Health: Tranexamic Acid Now Available OTC In France

 
• By David Ridley

Cemag Care may be behind the recent Rx-to-OTC switch of menstrual health treatment tranexamic acid (1000mg) in France.

US FDA Notes Honey Drops Eye Care, Nasal Spray Brain Boost In Recent Warning Letters

 
• By Malcolm Spicer

Recent FDA warning letters hit typical problems in consumer health space such as manufacturing quality control deficiencies, but also note honey offered for eye infections and nasal spray to enhance cognitive function.

More from Policy & Regulation

OMUFA Reauthorization: US FDA Would Identify Rx-OTC Switch Candidates, Work With Sponsors

 
• By Kate Rawson

Senate “SMART OTC” Act would require the FDA to identify product categories that could be eligible for an Rx-to-OTC switch and create a framework to work with sponsors.

Women’s Health: Tranexamic Acid Now Available OTC In France

 
• By David Ridley

Cemag Care may be behind the recent Rx-to-OTC switch of menstrual health treatment tranexamic acid (1000mg) in France.

Shutdown Approaches: US FDA Would Retain Most Of Recently Trimmed Staff

 
• By Derrick Gingery

FDA shutdown plans indicate about 86% of staff would be retained, a rate that is higher than previous plans, but reserve funding would not last more than a few months.